{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T01:11:42Z","timestamp":1794186702618,"version":"4.8.0"},"reference-count":300,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2018,1,23]]},"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation. PBC is most prevalent in women and those over the age of 50, but a spectrum of disease is recognised in adult patients globally; male sex, younger age at onset (&lt;45) and advanced disease at presentation are baseline predictors of poorer outcome. As the disease is increasingly diagnosed through the combination of cholestatic serum liver tests and the presence of antimitochondrial antibodies, most presenting patients are not cirrhotic and the term cholangitis is more accurate. Disease course is frequently accompanied by symptoms that can be burdensome for patients, and management of patients with PBC must address, in a life-long manner, both disease progression and symptom burden. Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients and risk stratification based on baseline and on-treatment factors, including in particular the response to treatment. Those intolerant of treatment with UDCA or those with high-risk disease as evidenced by UDCA treatment failure (frequently reflected in trial and clinical practice as an alkaline phosphatase &gt;1.67\u2009\u00d7 upper limit of normal and\/or elevated bilirubin) should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended agent. Follow-up of patients is life-long and must address treatment of the disease and management of associated symptoms.<\/jats:p>","DOI":"10.1136\/gutjnl-2017-315259","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T12:15:31Z","timestamp":1522239331000},"page":"1568-1594","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":325,"title":["The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines"],"prefix":"10.1136","volume":"67","author":[{"given":"Gideon M","family":"Hirschfield","sequence":"first","affiliation":[{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K","family":"Dyson","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"},{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme J M","family":"Alexander","sequence":"additional","affiliation":[{"name":"Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK"},{"name":"UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Collier","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit, Oxford University Hospitals, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"H\u00fcbscher","sequence":"additional","affiliation":[{"name":"Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"Department of Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Patanwala","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK"},{"name":"University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P","family":"Pereira","sequence":"additional","affiliation":[{"name":"Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK"},{"name":"UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK"},{"name":"Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collette","family":"Thain","sequence":"additional","affiliation":[{"name":"PBC Foundation, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[{"name":"Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK"},{"name":"UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Walmsley","sequence":"additional","affiliation":[{"name":"PSC Support, Didcot, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Webster","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E J","family":"Jones","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"},{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"2025121301024094000_67.9.1568.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309164"},{"key":"2025121301024094000_67.9.1568.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61965-4"},{"key":"2025121301024094000_67.9.1568.3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020712-164014"},{"key":"2025121301024094000_67.9.1568.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"2025121301024094000_67.9.1568.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"2025121301024094000_67.9.1568.6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26228"},{"key":"2025121301024094000_67.9.1568.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct074694"},{"key":"2025121301024094000_67.9.1568.9","first-page":"377","article-title":"The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease?","volume":"75","author":"Myszor","year":"1990","journal-title":"Q J Med"},{"key":"2025121301024094000_67.9.1568.10","doi-asserted-by":"publisher","DOI":"10.1053\/cgh.2003.50014"},{"key":"2025121301024094000_67.9.1568.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"2025121301024094000_67.9.1568.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.12.005"},{"key":"2025121301024094000_67.9.1568.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.029"},{"key":"2025121301024094000_67.9.1568.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22428"},{"key":"2025121301024094000_67.9.1568.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.031"},{"key":"2025121301024094000_67.9.1568.16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"key":"2025121301024094000_67.9.1568.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.003"},{"key":"2025121301024094000_67.9.1568.18","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.216"},{"key":"2025121301024094000_67.9.1568.19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1055\/s-0034-1383730","article-title":"The new epidemiology of primary biliary cirrhosis","volume":"34","author":"Griffiths","year":"2014","journal-title":"Semin Liver Dis"},{"key":"2025121301024094000_67.9.1568.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.025"},{"key":"2025121301024094000_67.9.1568.21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300213"},{"key":"2025121301024094000_67.9.1568.22","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt308"},{"key":"2025121301024094000_67.9.1568.23","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20197"},{"key":"2025121301024094000_67.9.1568.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.04.064"},{"key":"2025121301024094000_67.9.1568.25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/00365520701396034","article-title":"Prevalence and incidence of primary biliary cirrhosis are increasing in Finland","volume":"42","author":"Rautiainen","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MEG.0b013e328353753d","article-title":"The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study","volume":"24","author":"Baldursdottir","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/MEG.0b013e328277594a","article-title":"Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community","volume":"19","author":"Pla","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.28","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1111\/liv.12479","article-title":"Geoepidemiology and space-time analysis of primary biliary cirrhosis in Crete, Greece","volume":"34","author":"Koulentaki","year":"2014","journal-title":"Liver Int"},{"key":"2025121301024094000_67.9.1568.29","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int"},{"key":"2025121301024094000_67.9.1568.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23210"},{"key":"2025121301024094000_67.9.1568.31","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.gastro.2003.08.022","article-title":"Pediatric-onset primary biliary cirrhosis","volume":"125","author":"Dahlan","year":"2003","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/2005\/203028","article-title":"Characteristics of primary biliary cirrhosis in British Columbia\u2019s First Nations population","volume":"19","author":"Arbour","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-100"},{"key":"2025121301024094000_67.9.1568.34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26176"},{"key":"2025121301024094000_67.9.1568.35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.21759","article-title":"Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States","volume":"46","author":"Peters","year":"2007","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.36","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2013.12.010","article-title":"Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics","volume":"12","author":"Levy","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80097-X"},{"key":"2025121301024094000_67.9.1568.38","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hch078"},{"key":"2025121301024094000_67.9.1568.39","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21165"},{"key":"2025121301024094000_67.9.1568.40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20907"},{"key":"2025121301024094000_67.9.1568.41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21749"},{"key":"2025121301024094000_67.9.1568.42","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.184218"},{"key":"2025121301024094000_67.9.1568.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.019"},{"key":"2025121301024094000_67.9.1568.44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.05.005"},{"key":"2025121301024094000_67.9.1568.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810440"},{"key":"2025121301024094000_67.9.1568.46","doi-asserted-by":"publisher","DOI":"10.1038\/ng.789"},{"key":"2025121301024094000_67.9.1568.47","doi-asserted-by":"publisher","DOI":"10.1038\/ng.631"},{"key":"2025121301024094000_67.9.1568.48","doi-asserted-by":"publisher","DOI":"10.1038\/ng.627"},{"key":"2025121301024094000_67.9.1568.49","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2395"},{"key":"2025121301024094000_67.9.1568.50","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds359"},{"key":"2025121301024094000_67.9.1568.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.08.010"},{"key":"2025121301024094000_67.9.1568.52","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.89"},{"key":"2025121301024094000_67.9.1568.53","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12016-015-8472-0","article-title":"Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population","volume":"48","author":"Dong","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025121301024094000_67.9.1568.54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9019"},{"key":"2025121301024094000_67.9.1568.55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.clinre.2015.05.002","article-title":"Making the most of new genetic risk factors: genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"39","author":"Mells","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025121301024094000_67.9.1568.56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/gene.2015.2","article-title":"The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk","volume":"16","author":"Tang","year":"2015","journal-title":"Genes Immun"},{"key":"2025121301024094000_67.9.1568.57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0034-1383726","article-title":"Environmental factors in primary biliary cirrhosis","volume":"34","author":"Juran","year":"2014","journal-title":"Semin Liver Dis"},{"key":"2025121301024094000_67.9.1568.58","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.29760"},{"key":"2025121301024094000_67.9.1568.59","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21076"},{"key":"2025121301024094000_67.9.1568.60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23139"},{"key":"2025121301024094000_67.9.1568.61","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50446"},{"key":"2025121301024094000_67.9.1568.62","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.2.133"},{"key":"2025121301024094000_67.9.1568.63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.9.5874"},{"key":"2025121301024094000_67.9.1568.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197309272891306"},{"key":"2025121301024094000_67.9.1568.65","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.023937"},{"key":"2025121301024094000_67.9.1568.66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cld.2015.08.003","article-title":"Making sense of autoantibodies in cholestatic liver diseases","volume":"20","author":"Marzorati","year":"2016","journal-title":"Clin Liver Dis"},{"key":"2025121301024094000_67.9.1568.67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(65)91372-3","article-title":"Serological tests in diagnosis of primary biliary cirrhosis","volume":"1","author":"Walker","year":"1965","journal-title":"Lancet"},{"key":"2025121301024094000_67.9.1568.68","first-page":"237","article-title":"Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications","volume":"1","author":"Doniach","year":"1966","journal-title":"Clin Exp Immunol"},{"key":"2025121301024094000_67.9.1568.69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.126.2.277"},{"key":"2025121301024094000_67.9.1568.70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF00918255","article-title":"Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis","volume":"5","author":"Ruffatti","year":"1985","journal-title":"J Clin Immunol"},{"key":"2025121301024094000_67.9.1568.71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080438"},{"key":"2025121301024094000_67.9.1568.72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0016-5085(90)91246-3","article-title":"Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis","volume":"99","author":"Lassoued","year":"1990","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0016-5085(94)95333-3","article-title":"Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis","volume":"106","author":"Nickowitz","year":"1994","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.22.8654"},{"key":"2025121301024094000_67.9.1568.75","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240117"},{"key":"2025121301024094000_67.9.1568.76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21472"},{"key":"2025121301024094000_67.9.1568.77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0034-1383732","article-title":"Clinical significance of autoantibodies in primary biliary cirrhosis","volume":"34","author":"Nakamura","year":"2014","journal-title":"Semin Liver Dis"},{"key":"2025121301024094000_67.9.1568.78","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int"},{"key":"2025121301024094000_67.9.1568.79","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12423"},{"key":"2025121301024094000_67.9.1568.80","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00465-3"},{"key":"2025121301024094000_67.9.1568.81","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2036.2007.03433.x","article-title":"Antibodies to SS-A\/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis","volume":"26","author":"Granito","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121301024094000_67.9.1568.82","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.036558"},{"key":"2025121301024094000_67.9.1568.83","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(96)04410-8","article-title":"Natural history of early primary biliary cirrhosis","volume":"348","author":"Metcalf","year":"1996","journal-title":"The Lancet"},{"key":"2025121301024094000_67.9.1568.84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840060609"},{"key":"2025121301024094000_67.9.1568.85","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in healthy adults","volume":"27","author":"Mattalia","year":"1998","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.86","doi-asserted-by":"publisher","DOI":"10.1007\/s005350170111"},{"key":"2025121301024094000_67.9.1568.87","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.25.9.789"},{"key":"2025121301024094000_67.9.1568.88","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0009-8981(80)90353-8","article-title":"Serum IgM in primary biliary cirrhosis","volume":"108","author":"Taal","year":"1980","journal-title":"Clin Chim Acta"},{"key":"2025121301024094000_67.9.1568.89","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80098-1"},{"key":"2025121301024094000_67.9.1568.90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204"},{"key":"2025121301024094000_67.9.1568.91","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"2025121301024094000_67.9.1568.92","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22742"},{"key":"2025121301024094000_67.9.1568.93","doi-asserted-by":"crossref","unstructured":"Nakanuma YZY , Portmann B . Diseases of the bile ducts. In: Burt AD , Ferrell LD , eds. MacSween\u2019s pathology of the liver: Churchill Livingstone, 2012:491\u2013562.","DOI":"10.1016\/B978-0-7020-3398-8.00010-6"},{"key":"2025121301024094000_67.9.1568.94","unstructured":"Batts K . Autoimmune and chronic cholestatic disorders of the liver. In: Odze RD , Goldblum JR , Surgical pathology of the GI tract, liver, biliary tract and pancreas. Philadelphia: Elsevier Saunders, 2014."},{"key":"2025121301024094000_67.9.1568.95","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290444"},{"key":"2025121301024094000_67.9.1568.96","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31880"},{"key":"2025121301024094000_67.9.1568.97","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.49.7.556"},{"key":"2025121301024094000_67.9.1568.98","doi-asserted-by":"publisher","DOI":"10.4065\/73.2.179"},{"key":"2025121301024094000_67.9.1568.99","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80244-2"},{"key":"2025121301024094000_67.9.1568.100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2559.2006.02537.x","article-title":"Proposal of a new staging and grading system of the liver for primary biliary cirrhosis","volume":"49","author":"Hiramatsu","year":"2006","journal-title":"Histopathology"},{"key":"2025121301024094000_67.9.1568.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.09.017"},{"key":"2025121301024094000_67.9.1568.102","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/his.12384","article-title":"Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication","volume":"65","author":"Chan","year":"2014","journal-title":"Histopathology"},{"key":"2025121301024094000_67.9.1568.103","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/liv.12620","article-title":"Primary biliary cirrhosis: proposal for a new simple histological scoring system","volume":"35","author":"Wendum","year":"2015","journal-title":"Liver Int"},{"key":"2025121301024094000_67.9.1568.104","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26020"},{"key":"2025121301024094000_67.9.1568.105","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22517"},{"key":"2025121301024094000_67.9.1568.106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21151"},{"key":"2025121301024094000_67.9.1568.107","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25599"},{"key":"2025121301024094000_67.9.1568.108","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.109","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.110","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bpg.2011.10.005","article-title":"Diagnosis of primary biliary cirrhosis","volume":"25","author":"Hirschfield","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025121301024094000_67.9.1568.111","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.035"},{"key":"2025121301024094000_67.9.1568.113","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00144-1"},{"key":"2025121301024094000_67.9.1568.114","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-230X-11-95","article-title":"An increased risk of urinary tract infection precedes development of primary biliary cirrhosis","volume":"11","author":"Varyani","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"2025121301024094000_67.9.1568.115","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840150518"},{"key":"2025121301024094000_67.9.1568.116","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(93)90513-M"},{"key":"2025121301024094000_67.9.1568.117","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1572-0241.2008.02092.x","article-title":"Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study","volume":"103","author":"Solaymani-Dodaran","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.118","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.265"},{"key":"2025121301024094000_67.9.1568.119","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s10620-009-0988-9","article-title":"Statins in primary biliary cirrhosis: are they safe?","volume":"55","author":"Abu Rajab","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2025121301024094000_67.9.1568.120","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.121","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21741"},{"key":"2025121301024094000_67.9.1568.122","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2011.03.031","article-title":"Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.123","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21423"},{"key":"2025121301024094000_67.9.1568.124","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0016-5085(77)80011-5","article-title":"Presentation and course of asymptomatic primary biliary cirrhosis","volume":"72","author":"Long","year":"1977","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.125","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/0016-5085(90)91091-J","article-title":"Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study","volume":"98","author":"Balasubramaniam","year":"1990","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00770.x"},{"key":"2025121301024094000_67.9.1568.127","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.2.276"},{"key":"2025121301024094000_67.9.1568.128","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/hep.21678","article-title":"Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis","volume":"45","author":"Bogdanos","year":"2007","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.129","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.075002"},{"key":"2025121301024094000_67.9.1568.130","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100102"},{"key":"2025121301024094000_67.9.1568.131","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/00365520510023215","article-title":"Survival following the development of ascites and\/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model","volume":"40","author":"Chan","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.132","doi-asserted-by":"publisher","DOI":"10.1136\/gut.20.2.137"},{"key":"2025121301024094000_67.9.1568.133","first-page":"1148","article-title":"Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?","volume":"23","author":"Kilmurry","year":"1996","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.134","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.135","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22172"},{"key":"2025121301024094000_67.9.1568.136","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5852"},{"key":"2025121301024094000_67.9.1568.137","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318225db4d"},{"key":"2025121301024094000_67.9.1568.138","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.019"},{"key":"2025121301024094000_67.9.1568.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.029"},{"key":"2025121301024094000_67.9.1568.140","doi-asserted-by":"crossref","unstructured":"Hirschfield GM , Heathcote EJ . Primary biliary cirrhosis: evidence-based gastroenterology and hepatology. Oxford, UK: Wiley-Blackwell, 2010.","DOI":"10.1002\/9781444314403.ch32"},{"key":"2025121301024094000_67.9.1568.141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301903"},{"key":"2025121301024094000_67.9.1568.142","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.143","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(94)90861-3"},{"key":"2025121301024094000_67.9.1568.144","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1994.tb01237.x"},{"key":"2025121301024094000_67.9.1568.145","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70183-5"},{"key":"2025121301024094000_67.9.1568.146","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(95)90294-5"},{"key":"2025121301024094000_67.9.1568.147","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.1998.00395.x","article-title":"A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg\/kg or 20 mg\/kg. Dutch Multicentre PBC Study Group","volume":"12","author":"Van Hoogstraten","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121301024094000_67.9.1568.148","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20240"},{"key":"2025121301024094000_67.9.1568.149","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"2025121301024094000_67.9.1568.150","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00634.x"},{"key":"2025121301024094000_67.9.1568.151","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121301024094000_67.9.1568.152","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0521"},{"key":"2025121301024094000_67.9.1568.153","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25992"},{"key":"2025121301024094000_67.9.1568.154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.023"},{"key":"2025121301024094000_67.9.1568.155","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.019"},{"key":"2025121301024094000_67.9.1568.156","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.08.004"},{"key":"2025121301024094000_67.9.1568.157","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1092381"},{"key":"2025121301024094000_67.9.1568.158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"2025121301024094000_67.9.1568.159","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70351-3"},{"key":"2025121301024094000_67.9.1568.160","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20646"},{"key":"2025121301024094000_67.9.1568.161","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310209"},{"key":"2025121301024094000_67.9.1568.162","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27744"},{"key":"2025121301024094000_67.9.1568.163","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.164","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"2025121301024094000_67.9.1568.166","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04512.x"},{"key":"2025121301024094000_67.9.1568.167","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.02.011"},{"key":"2025121301024094000_67.9.1568.168","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121301024094000_67.9.1568.169","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2025121301024094000_67.9.1568.170","first-page":"148","article-title":"A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations","volume":"10","author":"Zhang","year":"2015","journal-title":"Prz Gastroenterol"},{"key":"2025121301024094000_67.9.1568.171","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26365"},{"key":"2025121301024094000_67.9.1568.172","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065862"},{"key":"2025121301024094000_67.9.1568.173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.12.012"},{"key":"2025121301024094000_67.9.1568.174","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.175","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1016\/S0168-8278(15)31349-0","article-title":"P1152: a\u00a0comparative study of pruritus in PBC cohorts from UK, USA and Italy","volume":"62","author":"Hegade","year":"2015","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.176","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0016-5085(76)80016-9","article-title":"The biliary system in primary biliary cirrhosis. A study by endoscopic retrograde cholangiopancreatography","volume":"70","author":"Summerfield","year":"1976","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.177","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis","volume":"50","author":"Datta","year":"1966","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.178","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00606.x"},{"key":"2025121301024094000_67.9.1568.179","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01235.x"},{"key":"2025121301024094000_67.9.1568.180","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23821"},{"key":"2025121301024094000_67.9.1568.181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25748"},{"key":"2025121301024094000_67.9.1568.182","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.183","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"key":"2025121301024094000_67.9.1568.184","first-page":"488","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampicin. Results of a double-blind, cross-over, randomized trial","volume":"94","author":"Podesta","year":"1991","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.185","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.186","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01200.x"},{"key":"2025121301024094000_67.9.1568.187","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01326.x"},{"key":"2025121301024094000_67.9.1568.188","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.3.436"},{"key":"2025121301024094000_67.9.1568.189","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2011.04158.x","article-title":"Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus","volume":"73","author":"Sampaziotis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2025121301024094000_67.9.1568.190","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"Bergasa","year":"1992","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.191","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9322521"},{"key":"2025121301024094000_67.9.1568.192","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00318-5"},{"key":"2025121301024094000_67.9.1568.193","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/95.8.547"},{"key":"2025121301024094000_67.9.1568.194","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00879-5"},{"key":"2025121301024094000_67.9.1568.195","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70225-3"},{"key":"2025121301024094000_67.9.1568.196","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21553"},{"key":"2025121301024094000_67.9.1568.197","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21370"},{"key":"2025121301024094000_67.9.1568.198","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.009"},{"key":"2025121301024094000_67.9.1568.199","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.21185","article-title":"Nasobiliary drainage for cholestatic pruritus","volume":"43","author":"Hofmann","year":"2006","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.200","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2036.2012.04994.x","article-title":"\u2018Out-patient\u2019 albumin dialysis for cholestatic patients with intractable pruritus","volume":"35","author":"Leckie","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121301024094000_67.9.1568.201","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jhep.2012.04.023","article-title":"Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study","volume":"57","author":"Decock","year":"2012","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.202","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.08.008"},{"key":"2025121301024094000_67.9.1568.203","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30204.x"},{"key":"2025121301024094000_67.9.1568.204","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290229"},{"key":"2025121301024094000_67.9.1568.205","first-page":"167A","article-title":"Fatigue, mental health and depression in patients with primary biliary cirrhosis (PBC)","volume":"24","author":"Huet","year":"1996","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.206","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.5.705"},{"key":"2025121301024094000_67.9.1568.207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01857.x"},{"key":"2025121301024094000_67.9.1568.208","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32993"},{"key":"2025121301024094000_67.9.1568.209","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22371"},{"key":"2025121301024094000_67.9.1568.210","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.04.013"},{"key":"2025121301024094000_67.9.1568.211","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.04.017","article-title":"The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study","volume":"59","author":"Carbone","year":"2013","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.212","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcn043"},{"key":"2025121301024094000_67.9.1568.213","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.022"},{"key":"2025121301024094000_67.9.1568.214","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/PL00009532","article-title":"Primary biliary cirrhosis, sicca complex, and dysphagia","volume":"12","author":"Mang","year":"1997","journal-title":"Dysphagia"},{"key":"2025121301024094000_67.9.1568.215","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.003889"},{"key":"2025121301024094000_67.9.1568.216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.02.010"},{"key":"2025121301024094000_67.9.1568.217","first-page":"465","article-title":"Diagnosis and management of Sj\u00f6gren syndrome","volume":"79","author":"Kruszka","year":"2009","journal-title":"Am Fam Physician"},{"key":"2025121301024094000_67.9.1568.218","unstructured":"National Institute for Health and Care Excellence (NICE). Raynaud\u2019s phenomenon. NICE clinical knowledge summary, 2014."},{"key":"2025121301024094000_67.9.1568.219","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.13794","article-title":"The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis","volume":"44","author":"Dyson","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121301024094000_67.9.1568.220","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cld.2015.08.013","article-title":"Utility of noninvasive markers of fibrosis in cholestatic liver diseases","volume":"20","author":"Corpechot","year":"2016","journal-title":"Clin Liver Dis"},{"key":"2025121301024094000_67.9.1568.221","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25993"},{"key":"2025121301024094000_67.9.1568.222","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"2025121301024094000_67.9.1568.223","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181a84b8d"},{"key":"2025121301024094000_67.9.1568.224","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"2025121301024094000_67.9.1568.225","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"2025121301024094000_67.9.1568.226","first-page":"175","article-title":"[Hepatocellular carcinoma - current aspects of screening, surveillance and therapeutic strategies (revised EASL-EORTC recommendations)]","volume":"139","author":"Roeb","year":"2014","journal-title":"Zentralbl Chir"},{"key":"2025121301024094000_67.9.1568.227","first-page":"1160","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis","volume":"96","author":"Caballer\u00eda","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.228","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2169\/internalmedicine.52.0010","article-title":"Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"52","author":"Tomiyama","year":"2013","journal-title":"Intern Med"},{"key":"2025121301024094000_67.9.1568.229","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33157"},{"key":"2025121301024094000_67.9.1568.230","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32832c788c"},{"key":"2025121301024094000_67.9.1568.231","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"2025121301024094000_67.9.1568.232","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309262"},{"key":"2025121301024094000_67.9.1568.233","unstructured":"National Institute for Health and Care Excellence (NICE). Cirrhosis in over 16s: assessment and management. London, 2016."},{"key":"2025121301024094000_67.9.1568.234","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(87)80035-1"},{"key":"2025121301024094000_67.9.1568.235","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MCG.0b013e3181f18c4e","article-title":"Varices in early histological stage primary biliary cirrhosis","volume":"45","author":"Ali","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"2025121301024094000_67.9.1568.236","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1440-1746.2012.07114.x","article-title":"Prevalence and associated factors with esophageal varices in early primary biliary cirrhosis","volume":"27","author":"Ikeda","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.237","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910102"},{"key":"2025121301024094000_67.9.1568.238","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"2025121301024094000_67.9.1568.239","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"2025121301024094000_67.9.1568.240","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26359"},{"key":"2025121301024094000_67.9.1568.241","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.242","unstructured":"National Institute for Health and Care Excellence (NICE). Rifaximin for preventing episodes of overt hepatic encephalopathy: Technology appraisal guidance, 2015."},{"key":"2025121301024094000_67.9.1568.243","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893"},{"key":"2025121301024094000_67.9.1568.244","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12803"},{"key":"2025121301024094000_67.9.1568.245","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04211.x"},{"key":"2025121301024094000_67.9.1568.246","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.247","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.131730"},{"key":"2025121301024094000_67.9.1568.248","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.249","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1600-6143.2009.03006.x","article-title":"Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation","volume":"10","author":"Montano-Loza","year":"2010","journal-title":"Am J Transplant"},{"key":"2025121301024094000_67.9.1568.250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12026-014-8594-0","article-title":"Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease","volume":"61","author":"Agmon-Levin","year":"2015","journal-title":"Immunol Res"},{"key":"2025121301024094000_67.9.1568.251","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04134.x"},{"key":"2025121301024094000_67.9.1568.252","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp188"},{"key":"2025121301024094000_67.9.1568.253","unstructured":"National Institute for Health and Care Excellence (NICE). Oesteoporosis: fragility fracture risk: osteoporosis: assessing the risk of fragility fracture. London, 2012."},{"key":"2025121301024094000_67.9.1568.254","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Gua\u00f1abens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.255","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20866"},{"key":"2025121301024094000_67.9.1568.256","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","author":"Gua\u00f1abens","year":"2013","journal-title":"Hepatology"},{"key":"2025121301024094000_67.9.1568.257","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2008.02.005"},{"key":"2025121301024094000_67.9.1568.258","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01026.x"},{"key":"2025121301024094000_67.9.1568.259","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"key":"2025121301024094000_67.9.1568.260","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.12"},{"key":"2025121301024094000_67.9.1568.261","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jhep.2014.09.010","article-title":"Unmet clinical need in autoimmune liver diseases","volume":"62","author":"Dyson","year":"2015","journal-title":"J Hepatol"},{"key":"2025121301024094000_67.9.1568.262","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007985","article-title":"RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial","volume":"5","author":"Jopson","year":"2015","journal-title":"BMJ Open"},{"key":"2025121301024094000_67.9.1568.263","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21583"},{"key":"2025121301024094000_67.9.1568.264","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaut.2010.09.005","article-title":"PBC screen: an IgG\/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis","volume":"35","author":"Liu","year":"2010","journal-title":"J Autoimmun"},{"key":"2025121301024094000_67.9.1568.265","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12016-010-8234-y","article-title":"Overcoming a \"probable\" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature","volume":"42","author":"Bizzaro","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025121301024094000_67.9.1568.266","first-page":"124","article-title":"A study of antimitochondrial antibodies in a random population in Estonia","volume":"92","author":"Turchany","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.267","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04410-8"},{"key":"2025121301024094000_67.9.1568.268","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.4.589"},{"key":"2025121301024094000_67.9.1568.269","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22380"},{"key":"2025121301024094000_67.9.1568.270","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05223.x"},{"key":"2025121301024094000_67.9.1568.271","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cld.317","article-title":"Overlap syndrome: a real syndrome?","volume":"3","author":"Haldar","year":"2014","journal-title":"Clin Liver Dis"},{"key":"2025121301024094000_67.9.1568.272","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280203"},{"key":"2025121301024094000_67.9.1568.273","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.002"},{"key":"2025121301024094000_67.9.1568.274","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"9","author":"Bonder","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.275","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1440-1746.2009.06018.x","article-title":"Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes","volume":"25","author":"Yokokawa","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.276","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01136.x"},{"key":"2025121301024094000_67.9.1568.277","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cgh.2013.11.030","article-title":"Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis","volume":"12","author":"Trivedi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121301024094000_67.9.1568.278","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2015.03.020"},{"key":"2025121301024094000_67.9.1568.279","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1155\/2008\/969826","article-title":"Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports","volume":"22","author":"Alallam","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"2025121301024094000_67.9.1568.280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/17453054.2011.548794","article-title":"Development of an evidence-based patient information medium: empowering newly diagnosed patients with primary biliary cirrhosis","volume":"34","author":"Pearce","year":"2011","journal-title":"J Vis Commun Med"},{"key":"2025121301024094000_67.9.1568.281","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01500.x"},{"key":"2025121301024094000_67.9.1568.282","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.1999.tb00020.x"},{"key":"2025121301024094000_67.9.1568.283","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.010"},{"key":"2025121301024094000_67.9.1568.284","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.8.1200"},{"key":"2025121301024094000_67.9.1568.285","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834bb951"},{"key":"2025121301024094000_67.9.1568.286","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044456"},{"key":"2025121301024094000_67.9.1568.287","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.024"},{"key":"2025121301024094000_67.9.1568.288","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21665"},{"key":"2025121301024094000_67.9.1568.289","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03701.x"},{"key":"2025121301024094000_67.9.1568.290","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03825.x"},{"key":"2025121301024094000_67.9.1568.291","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.010"},{"key":"2025121301024094000_67.9.1568.292","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0016-5085(89)91574-6","article-title":"Intestinal malabsorption of vitamin E in primary biliary cirrhosis","volume":"96","author":"Sokol","year":"1989","journal-title":"Gastroenterology"},{"key":"2025121301024094000_67.9.1568.293","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(03)00097-7"},{"key":"2025121301024094000_67.9.1568.294","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.7050"},{"key":"2025121301024094000_67.9.1568.295","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12016-014-8446-7","article-title":"Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025121301024094000_67.9.1568.296","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260508"},{"key":"2025121301024094000_67.9.1568.297","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308351"},{"key":"2025121301024094000_67.9.1568.298","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/gut.45.5.756","article-title":"Cancer risk in primary biliary cirrhosis: a study in northern England","volume":"45","author":"Howel","year":"1999","journal-title":"Gut"},{"key":"2025121301024094000_67.9.1568.299","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840150518"},{"key":"2025121301024094000_67.9.1568.300","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.11.036"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2017-315259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T09:02:58Z","timestamp":1765616578000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2017-315259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":300,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,8,13]]},"published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1136\/gutjnl-2017-315259"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2017-315259","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]}}}